Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial to Assess the Efficacy of µSmin® Plus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04101201
Recruitment Status : Completed
First Posted : September 24, 2019
Last Update Posted : June 25, 2020
Sponsor:
Collaborator:
Opera CRO, a TIGERMED Group Company
Information provided by (Responsible Party):
Giellepi S.p.A

Brief Summary:
This study evaluates treatment with the dietary supplement µSmin® Plus in a group of patients suffering from chronic venous insufficiency in comparison with a similarly-sized group of patients receiving placebo evaluated by quality of life questionnaires, VAS pain scale, CVI symptomatology, and change in the circumference of the affected leg at calf level

Condition or disease Intervention/treatment Phase
Chronic Venous Disease Dietary Supplement: µSmin® Plus Other: Placebo Not Applicable

Detailed Description:
In this study we use a dietary supplement - µSmin® Plus - for symptomatic treatment of CVI and we will monitor its impact on CVI symptoms, features, and consequences (item) of the disease listed below: limb edema, walking, daily tasks performance, pain/burning symptoms, pruritus/paresthesis, sensation of heaviness/fatigue, time wasted in the management of the disease, social burden, disease impact on self-confidence, and its impact on physical exercise/recreational activities. Results of related clinical trials were published before showing that this is an active field in clinical reasearch.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 73 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Diosmin is a naturally occurring flavonoid present in citrus fruits and other plants belonging to the Rutaceae family. It is used for the treatment of chronic venous insufficiency (CVI) for its pheblotonic and vaso-active properties, safety and tolerability as well.

µSmin® Plus is a proprietary flavonoid complex with enhanced bio-efficacy. It contains highly concentrated micronized and standardized Diosmin. Highly improved bioavailability and improved oral absorption by micronization of the particles.

Masking: Double (Participant, Investigator)
Primary Purpose: Supportive Care
Official Title: Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy of µSmin® Plus (Dietary Supplement) in Chronic Venous Insufficiency Symptoms Relief
Actual Study Start Date : November 15, 2019
Actual Primary Completion Date : April 24, 2020
Actual Study Completion Date : April 24, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
µSmin® Plus
µSmin® Plus is a new Micronized Diosmin Formulation for oral administration. Diosmin is extremely well tolerated and safe to use. Diosmin is safe for most people when used short-term for up to 6 months. During the 8 weeks of the clinical investigation, the subject will administer 1 tablet of µSMIN® Plus (corresponding to 450 mg of micronized diosmin) or placebo per day.
Dietary Supplement: µSmin® Plus
µSmin® Plus is a new Micronized Diosmin Formulation for oral administration. Diosmin is extremely well tolerated and safe to use. Diosmin is safe for most people when used short-term for up to 6 months. During the 8 weeks of the clinical investigation, the subject will administer 1 tablet of µSMIN® Plus (corresponding to 450 mg of micronized diosmin) or placebo per day.

Placebo Comparator: Placebo
It will be supplied by the Sponsor in an amount enough for the duration of the study. The subject will administer 1 tablet per day
Other: Placebo
It will be supplied by the Sponsor in an amount enough for the duration of the study. The subject will administer 1 tablet per day




Primary Outcome Measures :
  1. Quality of life assessed [ Time Frame: 56 days ]
    Quality of life is assessed by ChronIc Venous Insuficiency quality of life Questionnaire ( CIVIQ-20 questionnaire ). The 20-item questionnaire, provides a global index and an outline of 4 quality-of-life dimensions-"pain" (4 items), "physical" (4 items), "psychological" (9 items), and "social" (3 items). Items on the CIVIQ-20 scale were scored from 1 to 5. There are 20 questions in the CIVIQ-20, each with 5 possible answers (1 to 5), the minimum possible score being 20 and the maximum 100. In order to calculate the GIS, the difference between the final score and the minimum possible score is to be divided by the difference between the theoretical maximum and minimum scores (100-20=80), multiplied by 100. A low score will correspond to greater patient comfort.

  2. Change in the circumference of each affected leg [ Time Frame: 56 days ]
    To evaluate the efficacy of the dietary supplement µSmin® Plus on ameliorating the symptoms of Chronic Venous Insufficiency in terms of change in the circumference of affected legs and quality of life, in comparison with placebo, from baseline to week 8 visit; The unit for this measurement is centimeter.


Secondary Outcome Measures :
  1. Visual Analogue Scale ( VAS scale ) from 0 to 10 for pain measurements [ Time Frame: 56 days ]
    Visual Analogue Scale is a straight horizontal line of 100 mm. The ends are defined as the extreme limits of the pain (symptom, pain, health) orientated from the left (worst) to the right (best). Using a ruler, the score is determined by measuring the distance in millimeters on the 10 centimeters line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity and a low score indicates a low pain intensity.

  2. Symptoms relief assessed by Venous Clinical Severity Score (VCSS) questionnaire [ Time Frame: 56 days ]
    Venous Clinical Severity Score use the progressive ranking of severity, while weighting the upper levels representing the more severe presentations of Chronical Venous Disease. The lowest possible score is 0=absent meaning that the patient has no symptoms and the highest possible score is 30=sever meaning that the patient has a very severe venous symptoms.

  3. Investigator Global Assessment of the efficacy by scoresproduct [ Time Frame: 56 days ]
    Efficacy of treatment: Percentage of physicians who rated 1= excellent, 2 = good, 3= fair, 4= poor

  4. Patient Global Assessment of the efficacy by scores [ Time Frame: 56 days ]
    Patients satisfaction: 1= very satisfied, 2= satisfied, 3 = adequate, 4= unsatisfied, 5 = very unsatisfied

  5. Percentage of subjects who would want to continue with µSmin® Plus. [ Time Frame: 56 days ]
    By this outcome we want to find out the percentage of patients who will want to continue with µSmin® Plus.

  6. Percentage of subjects who experienced symptoms relief [ Time Frame: 56 days ]
    Percentage of subjects who experienced symptoms relief within the first week of intake, within 2 weeks of intake, or more than 2 weeks of intake;

  7. Treatment compliance [ Time Frame: 56 days ]
    Variable medication possession ratio (VMPR) will be used to calculate the compliance (or adherence) to the treatment in the two groups collected by diary card and used and unused products

  8. AE/SAE incidence [ Time Frame: 56 days ]
    Evaluation of safety during all the study period through AE/SAE collection

  9. Investigator Global Assessment of Safety (IGAS): [ Time Frame: 56 days ]
    Investigator Global Assessment of Safety (IGAS): using the 4-point scale:1= very good safety, 2 = good safety, 3 = moderate safety and 4 = poor safety. IGAS will be evaluated at the last visit.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female with age ≥18 and ≤60 with chronic venous insufficiency;
  • The chronic venous insufficiency must be graded between C2-C4 on the Clinical-Etiology-Anatomy-Pathophysiology (CEAP) classification system;
  • Able to communicate adequately with the investigator and to comply with the requirements for the entire study;
  • Capable of and freely willing to provide written informed consent prior to participating in the study;
  • Light smokers (<10 cigarettes per day).

Exclusion Criteria:

  • Patients suffering from other or associated vascular diseases, diabetes or bleeding disorders;
  • Oedema of the lower limbs of cardiac, renal or hepatic origin;
  • Presence of symptoms and/or trophic disorders of arterial, metabolic, neurological or orthopedic origin including traumas, arthritis, neuropathy;
  • One or more factors likely to affect venous symptoms such as recent childbirth, recent stripping, or deep or superficial venous thrombosis of the lower limbs during the previous 6 months;
  • Obese subjects (BMI > 30);
  • Hypersensitivity to active principles contained in the tested food supplement (diosmin);
  • Patients considered smokers (≥10 cigarettes/day);
  • Patients with concomitant or history of addiction to alcohol, spices or drug abuse;
  • Pregnant women, nursing mothers, or women (only if childbearing potential) not using adequate methods of contraception;
  • Participation in an interventional clinical study in the previous 30 days;
  • Presence of any clinically significant medical condition judged by the investigator to preclude the patient's inclusion in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04101201


Locations
Layout table for location information
Romania
SCM Gados
Timisoara, Timis, Romania, 300425
Sponsors and Collaborators
Giellepi S.p.A
Opera CRO, a TIGERMED Group Company
Investigators
Layout table for investigator information
Principal Investigator: Doina Rosu, MD SCM Dr. Rosu
Publications:

Layout table for additonal information
Responsible Party: Giellepi S.p.A
ClinicalTrials.gov Identifier: NCT04101201    
Other Study ID Numbers: CR2019/21
First Posted: September 24, 2019    Key Record Dates
Last Update Posted: June 25, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No